Sign in

You're signed outSign in or to get full access.

Jook Yuen Low

Director at BioNexus Gene Lab
Board

About Jook Yuen Low

Independent director of BioNexus Gene Lab Corp. since November 5, 2024; age 46 at appointment and 48 as of the 2025 proxy period. Holds an LL.B. and a Master of Business in Public Relations from Queensland University of Technology; admitted as Advocate & Solicitor of the High Court of Malaya in 2004; partner at Azura Mokhtar & Low with 20+ years’ legal experience in conveyancing, corporate law, and wealth management consulting .

Past Roles

OrganizationRoleTenureCommittees/Impact
High Court of MalayaAdvocate & SolicitorSince 2004Legal practice credential
Azura Mokhtar & LowPartnerOngoingCorporate law, banking transactions, property/real estate advisory

External Roles

OrganizationRoleTenureNotes
Azura Mokhtar & LowPartner (law firm)OngoingFocus areas: conveyancing, corporate agreements, wealth management consulting

Board Governance

  • Independence: Determined “independent” under Nasdaq Rule 5605(a)(2); Board has majority independent directors .
  • Committees: Member, Audit Committee (Chair: Chee Keong Yap); Member, Nominating & Corporate Governance Committee (Chair: Muhammad Azrul) .
  • Attendance and engagement:
    • Board: 4 meetings in FY2024; Ms. Low attended 1 board meeting after her November 5, 2024 appointment .
    • Committees: FY2024 included 4 Audit Committee meetings aligned to quarterly reporting and 2 executive sessions of independent directors; 2 meetings each for Nominating & Corporate Governance and Compensation Committees .
  • Lead Independent Director: Board had not appointed a lead independent director given size; independent directors meet with auditors without management .

Fixed Compensation

ComponentAmountFrequencyNotes
Independent Director Cash Retainer$1,000Per monthStandard independent director compensation
Implied Annual Retainer$12,000Per yearDerived from monthly rate; no additional fees disclosed

Performance Compensation

  • Equity awards/option grants to Ms. Low: Not specified in cited filings. Company’s 2024 Equity Incentive Plan authorizes director awards (options, SARs, restricted stock, other stock-based awards), with plan features summarized below .
Plan FeatureTermsSource
Option strike at grant≥ Fair Market Value; 10% owners ≥ 110% FMV
Option term and vestingDefault 5-year term (max 10); typical vesting in five annual installments on March 31
SARsStrike = FMV; payable in cash or shares; can be tandem with options
Restricted stockVoting/dividends; subject to forfeiture and restricted period
Other stock-based awardsMay include performance shares, convertible securities; can be performance-based
Change-in-controlCommittee discretion to accelerate vesting, assume/continue awards, or cash-out
Clawback/anti-hedgingAwards subject to recoupment; exchange rules and Dodd-Frank §954 compliance

Other Directorships & Interlocks

Company/OrganizationRoleCommittee RolesNotes
None disclosed in company’s director background sectionBackground for Ms. Low lists legal practice and firm partnership; no other public boards noted

Expertise & Qualifications

  • Legal and governance: Corporate governance, legal compliance, audit oversight; background spans corporate agreements, banking transactions, and property/real estate .
  • Committee-aligned skills: Audit and governance committee member, consistent with legal and compliance expertise .

Equity Ownership

Metric2025-01-312025-11-14
Shares Beneficially Owned12,616 1,261
Ownership % of Outstanding0.70% (based on 17,967,663 shares outstanding) 0.07%

Notes:

  • The company effected charter amendments in 2025; Articles of Amendment dated April 1, 2025 are referenced in later filings, consistent with post–reverse-split share counts .

Governance Assessment

  • Strengths:
    • Independence and committee placement enhance oversight in audit and governance .
    • Legal credentials suit governance and compliance duties .
    • Clear board use of executive sessions and regular audit cadence in FY2024 .
  • Alignment:
    • Cash retainer structure is modest; beneficial ownership (albeit small) provides some alignment; equity awards for directors are authorized under the plan though none are specified for Ms. Low in filings cited .
  • Potential conflicts/related-party exposure:
    • No family relationships among directors/executives; Ms. Low deemed independent; no selection arrangements disclosed; no related party ties are indicated in the cited disclosures .
  • Attendance:
    • Appointment late in FY2024 explains limited board meeting attendance (1 of 4); committee meeting frequency indicates structured oversight .

RED FLAGS:

  • None identified in cited documents specific to Ms. Low (no hedging/pledging disclosures, tax gross-ups, option repricing, or related-party transactions noted in the filings reviewed) .